Stromal B Lymphocytes Affecting Prognosis in Triple-Negative Breast Cancer by Opal/TSA Multiplexed Immunofluorescence
Min Fang,Wei Yin,Chunyan Qiu,Tao Song,Baihua Lin,Ying Wang,Hanchu Xiong,Shixiu Wu
DOI: https://doi.org/10.2147/ijwh.s444202
2024-04-30
International Journal of Women s Health
Abstract:Min Fang, 1, 2 Wei Yin, 3 Chunyan Qiu, 4 Tao Song, 2 Baihua Lin, 2 Ying Wang, 2 Hanchu Xiong, 2 Shixiu Wu 1 1 Department of Radiation Oncology, The Affiliated Hangzhou Hospital of Nanjing Medical University, Hangzhou, Zhejiang, People's Republic of China; 2 Cancer Center, Department of Radiation Oncology, Zhejiang Provincial People's Hospital(Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China; 3 Department of Radiation Oncology, Hangzhou Cancer Hospital, Hangzhou, Zhejiang, People's Republic of China; 4 National Cancer Center/National Clinical Research Center for Cancer/ Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, People's Republic of China Correspondence: Wei Yin, Department of Radiation Oncology, Hangzhou Cancer Hospital, Hangzhou, Zhejiang, People's Republic of China, Email Shixiu Wu, Department of Radiation Oncology, The Affiliated Hangzhou Hospital of Nanjing Medical University, Hangzhou, Zhejiang, People's Republic of China, Email Objective: Immune cells play a key role in tumor microenvironment. The purpose of this study was to investigate the infiltration and clinical indication of immune cells including their combined prognostic value in microenvironment of triple negative breast cancer. Methods: We investigated 100 patients with triple negative breast cancer by Opal/Tyramide Signal Amplification multispectral immunofluorescence between 2003 and 2017 at Zhejiang Provincial people's Hospital. Intratumoral and stromal immune cells of triple negative breast cancer were classified and quantitatively analyzed. Survival outcomes were compared using the Kaplan–Meier method and further analyzed with multivariate analysis. Results: Infiltration level of stromal B lymphocytes, stromal and intratumoral CD8+ T cells, stromal CD4+ T cells, stromal PD-L1 and intratumoral tumor associated macrophages 2 cells were shown as independent factors affecting disease-free survival and overall survival in univariate analysis. Stromal B lymphocytes, T stage, N stage and pathological type were independent predictive factors for both DFS and OS in multivariate analysis. We firstly found that patients with B lymphocytes-enriched subtypes have a better prognosis than those with T lymphocytes-enriched subtypes and tumor-associated macrophage-enriched subtypes. Conclusion: The present study identified a bunch of immune targets and subtypes, which could be exploited in future combined immunotherapy/chemotherapy strategies for triple negative breast cancer patients. Keywords: triple negative breast cancer, B lymphocytes, T lymphocytes, tumor associated macrophages, multispectral immunofluorescence, prognosis Triple-negative breast cancer (TNBC) is a subtype of breast cancer (BC) that does not express estrogen (ER), progesterone receptors (PR) and human epidermal growth factor receptor type 2 (HER2). It is noted for its power to impact younger females, metastasize early in spite of optimal adjuvant therapy and bring a miserable prognosis. 1 Nowadays, with limited targeted therapy options, standard of care for TNBC remains chemotherapy. Although TNBC is the subtype with the most complete response to chemotherapy (22%), the metastasis and recurrence rate of TNBC patients was still higher than non-TNBCs. 2 Recently, immunotherapy has become a new choice for tumor treatment which has the advantages of high specificity and little side effects. 3 Programmed death receptor-1 (PD-1) and programmed death ligand 1 (PD-L1) play an important role in the activation of T lymphocytes. PD-1:PD-L1 signal pathway mediates immune escape and immune tolerance in breast cancer and other tumors. Immunotherapeutics targeting the inhibitory receptors (IRs) PD-1 or PD-L1 have made substantial clinical progress in multiple cancer such as non–small-cell lung cancer. 4 In 2019, the Food and Drug Administration (FDA) of the United States has approved PD-L1 monoclonal antibody (atezolizumab) combined with chemotherapy as the first-line treatment of unresectable locally advanced or metastatic PD-L1 positive TNBC which can gain survival benefits. Moreover, only a small percentage of TNBC patients may experience a dramatic response to Immune Checkpoint Blocking (ICB). 5,6 It has been found that tumor infiltrating immune cells can predict the efficacy of immunotherapy with PD-1/PD-L1 inhibitors in patients with TNBC. For example, Schmid et al showed that patients with high expression of tumor infiltrating immune cells had greater clinical benefits with PD-1 treatment (12.6m -Abstract Truncated-
obstetrics & gynecology